Research and Industry Collaboration Opportunities

Enterprise Innovation brings internal and external collaboration opportunities to our faculty and trainees. These programs provide extra funding and opportunities to work with industry to advance faculty/trainees' translational research projects. 

1. Daiichi Sankyo Sponsored Research

Daiichi-Sankyo (DS), a well-known Japanese pharma, has initiated a new innovation program related to ideas which may pave the way to drug discovery and development. DS is now soliciting and accepting brief, non-confidential pre-proposals for review. Successful proposals will be considered for a research collaboration with funding up to $230,000 (including overhead/indirect costs) and spanning between 1-3 years in duration that align with their priority scopes of interest (more detailsPDF icon here).

If you are interested in exploring this opportunity, please send Deanna Scarcella (des4016@med.cornell.edu) a NON-CONFIDENTIAL, one-page overview of the proposed research collaboration using the suggested format below.

Suggested format for overview: 

  • Project title
  • Introduction/Background
  • Strategy/Method/Target/Modality
  • Significance/Novelty/Uniqueness
  • Publication
  • One figure (optional)

 There is a rolling submission, so please send the pre-proposal by Thursday, February 19, 2024 for review by the CTL team who would be glad to assist you with the preparation of a competitive, successful pre-proposal and ensure the Daiichi-Sankyo due date of March 1, 2024 is met.

2. CSL Research Acceleration Initiative

CSL is a leading global biotech company that develops and delivers innovative biotherapies to help people living with life-threatening medical conditions live full lives. CSL’s Research Acceleration Initiative aims to fast-track discovery of innovative biotherapies through partnerships between CSL and global research organizations.

Successful applicants will receive funding of up to $400,000 over 2 years. Interested researchers are invited to:

  • Attend information webinars to learn more about the initiative: Webinars will be held on:

Wednesday, 1/17/24, 4pm ET
Monday, 2/5/24 12pm ET

Contact Deanna Scarcella at des4016@med.cornell.edu to obtain webinar links and online application submission instructions.

  • Send Deanna Scarcella (des4016@med.cornell.edu) a NON-CONFIDENTIAL (make sure to EXCLUDE any unpublished data or information) abstract by Tuesday, 2/20/24 which will be reviewed by the Center for Technology Licensing (CTL). Please note: CTL will upload it to the CSL online portal by Tuesday, 2/27/24.

Learn more about the CSL Research Acceleration Initiative and its focus areasPDF icon here

3. The Center for Innovative NeuroTech Advancement (CINTA) & NeuroTech Harbor (NTH) Cycle 4 Award

The Center for Innovative NeuroTech Advancement (CINTA) & NeuroTech Harbor (NTH) announce the Cycle 4 Award Competition supported by the NIH Blueprint MedTech Program. This program is seeking collaborative projects aimed at developing emerging technologies into commercially viable, clinically focused solutions for disorders of the nervous system.

CINTA and NTH are calling for proposals leading to commercialization of groundbreaking preventative, therapeutic, and/or diagnostic medical devices. At a minimum, projects should have already clearly demonstrated proof-of-concept. The technologies proposed must have a pathway to a prototype ready for first-in-human testing within 4 years and have a viable pathway to commercial development.

Applications must focus on an intended use involving the nervous system or addressing consequences of such a disease or injury in an area of interest of the Participating Institutes/Centers.

Two kinds of awards may be issued for applications submitted to this solicitation:

  • Optimizer awards will rarely exceed $500,000 in direct costs per year for a period of up to 4 years. In addition to monetary support, awardees will receive mentoring and resources and support services necessary for translation will be available.
  • Seedling awards provide support for six months, a $25,000 stipend, and $25,000 to hire subject matter experts. Mentors will work with awardees throughout the project to help resolve specifically identified gap on the path to commercialization.

Applicants must submit pre-proposals through the Blueprint MedTech: Incubator Hubs Program online application system no later than 11:59 pm ET on February 29, 2024. Pre-proposals are submitted through a simple online application form equivalent to approximately three pages.

Eligible applicants will be invited to submit full proposals through the same online application system. The full proposal form is equivalent to approximately ten pages and will undergo review by CINTA and NTH.

To learn more about the award and apply, visit their website here. Weekly informational webinars and office hours by appointment are available in February 2024. 

4. The Mark Foundation Endeavor Awards

The Mark Foundation Endeavor Awards support collaborative research projects that bring together investigators with diverse areas of expertise to tackle challenges in the prevention, diagnosis, and treatment of cancer. These grants are awarded to teams of three or more investigators to generate and integrate data from diverse lines of research and transform those insights into advances for cancer patients that could not be achieved by individual efforts. 

Endeavor Awards are $3,000,000 disbursed over a 3-year term.

  • The requested funding should be divided amongst team members in a manner proportional to the actual cost of the work carried out by each investigator for the project.
  • The budget limit includes both direct and indirect costs, with indirect costs not to exceed 10% of the direct costs.
  • The third year of funding will be contingent on sufficient scientific progress as presented at the 18-month project review.
  • The letter of agreement will include IP terms with a revenue sharing component

Grants portal opens for submission of Letters of Intent (LOI) on 1/3/24. LOI submission deadline is 3/12/24. To learn more about the eligibility and LOI guidelines, please visit The Mark Foundation website here. 

5. The Mark Foundation Emerging Leader Award

The Mark Foundation Emerging Leader Awards support innovative cancer research from the next generation of leaders. These grants are awarded to outstanding early career investigators to support high-impact, high-risk projects that are distinct from their current research portfolio.

Award Terms

  • The grant amount is $250,000 per year for three (3) years totaling $750,000.
  • Indirect costs are not to exceed 10% of direct costs and are included in total.
  • Emerging Leader Awards are granted to a single investigator; co-investigators are not permitted. The award may be used to support projects carried out with collaborators, who may provide letters of support.
  • In Year 3, at The Mark Foundation’s discretion, select Awardees may be invited to apply for up to two (2) years of additional funding depending on project progress.
  • The letter of agreement will include IP terms with a revenue sharing component.
  • Award start date will be January 1, 2025.

The portal to submit letters of intent for the upcoming Emerging Leader Award will open on March 20, 2024. Letters of Intent must be submitted through the online application system no later than 5 PM Eastern Time on Monday, April 29, 2024. Learn more about the application process here

6. Critical Path Institute (C-Path) Translational Therapeutics Accelerator (TRxA) 2024 RFP for Breakthrough Research and Innovation In Drug Development Grants (BRIDGe)

BRIDGe awards are designed to support academic researchers by providing funding and defining optimal strategies for advancing new, cutting-edge therapeutics from the lab to patients. Projects eligible for BRIDGe awards include early lead optimization and IND-enabling studies, using small molecule approaches, anywhere in the world. Biologicals, including peptides or antibodies, oligonucleotides, cell and gene therapy applications and medical devices are not eligible at this time. Drug repurposing approaches are also not eligible during this funding cycle.

Please see attached documents for the PDF icon details of the funding opportunity and also a PDF icon pre-proposal template. To apply, send Deanna Scarcella (des4016@med.cornell.edu) a NON-CONFIDENTIAL (make sure to EXCLUDE any unpublished data or information) pre-proposal by Friday, March 22, 2024, which will be reviewed by the CTL. CTL will coordinate submitting the pre-proposal by the deadline of Fri, Mar 29. Contact Deanna if you have any questions. 

You are also invited to register for the 2024 TRxA Funding Opportunities webinar at 10 a.m. ET, Tuesday, January 30. Content will include an overview of the types of projects TRxA funds, eligibility criteria for TRxA awards, and a live Q&A. For more information, visit CPath.org.